PBI4050

DRUG3 trials

Sponsors

Liminal BioSciences Ltd.

Conditions

Cystic FibrosisIdiopathic Pulmonary Fibrosis (IPF)Metabolic SyndromeType 2 Diabetes

Phase 2

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT02538536

Liminal BioSciences Ltd.Idiopathic Pulmonary Fibrosis (IPF)

Start: 2015-07-31End: 2017-01-31Updated: 2019-04-17

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

CompletedNCT02562573

Liminal BioSciences Ltd.Metabolic Syndrome, Type 2 Diabetes

Start: 2015-05-31End: 2016-11-30Updated: 2017-04-11

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

TerminatedNCT02955888

Liminal BioSciences Ltd.Cystic Fibrosis

Start: 2017-01-03End: 2018-02-28Updated: 2020-12-08